Santen PharmaceuticalSANTEN PHARMACEUTICAL CO.,LTD.4536東証プライム医薬品FY ending Mar 2024, consolidated, IFRS

What does Santen Pharmaceutical do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

Figures for this period are incomplete, so the chart cannot be drawn.

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income¥26.6B

Operating cash flow¥72.6B

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow¥72.6B

Net income¥26.6B

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (4)

EDINET (FSA Japan)
有価証券報告書－第114期(2025/04/01－2026/03/31)
ID S100YDH12026-06-18Open
EDINET (FSA Japan)
有価証券報告書－第111期(2022/04/01－2023/03/31)
ID S100R54I2023-06-27Open
EDINET (FSA Japan)
有価証券報告書－第110期(令和3年4月1日－令和4年3月31日)
ID S100OEK12022-06-24Open
EDINET (FSA Japan)
有価証券報告書－第109期(令和2年4月1日－令和3年3月31日)
ID S100LRJK2021-06-25Open

Extracted from XBRL: 10 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.